Endogenous catecholamines modulate growth hormone release in the conscious rat during hypoglycaemia but not in the basal state.
To investigate the role of endogenous catecholamines and 5-hydroxytryptamine in the control of growth hormone (GH) secretion, secretory profiles of GH and prolactin were measured in conscious, male rats following intravenous administration of either 1) alpha 2 antagonist idazoxan 2 mg/kg, a dose that blocked alpha 2 agonist induced GH rise, 2) alpha 1 antagonist prazosin 1 mg/kg, 3) non-specific beta-blocker propranolol 1.5 mg/kg, a dose that prevented beta 2 agonist (salbutamol) induced inhibition, 4) serotonin antagonist cyproheptadine 0.5 mg/kg, a dose that inhibited serotonin agonist quipazine induced GH rise, or 5) control. No drug altered mean GH or prolactin levels and pulsatile GH release persisted. Unilateral injections of prazosin, propranolol and idazoxan were made into the medial basal hypothalamus and preoptic-anterior hypothalamic area and of cyproheptadine into the medial basal hypothalamus, all with no effect on short-term GH release. GH and prolactin secretory profiles were measured after giving rats 6 units/kg intravenous insulin. Blood glucose levels fell to less than 50% basal. Hypoglycaemia caused a non-significant 30% fall in mean 2 h GH. Intravenous idazoxan, prazosin, propranolol and cyproheptadine (doses as in first study) did not modify the blood glucose fall, but idazoxan produced a significant reduction of mean GH compared to insulin alone (4 +/- 1.1 ng/ml SEM, idazoxan/insulin versus 16 +/- 5.6 ng/ml, saline/insulin). The lack of an effect of alpha- and beta-blockers on normal, pulsatile GH release is against a role for endogenous catecholamines in controlling this release.(ABSTRACT TRUNCATED AT 250 WORDS)
Chapman
I M
IM
Centre for Neuroscience, Flinders University and Medical Centre, Adelaide, South Australia.
Kapoor
R
R
Willoughby
J O
JO
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002395:Catecholamines / Q000502:physiology*; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D007003:Hypoglycemia / Q000378:metabolism*; D007031:Hypothalamus; D007267:Injections; D007275:Injections, Intravenous; D008297:Male; D011388:Prolactin / Q000097:blood; D011863:Radioimmunoassay; D051381:Rats; D012701:Serotonin / Q000502:physiology; D012702:Serotonin Antagonists
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D001786:Blood Glucose; D002395:Catecholamines; D012702:Serotonin Antagonists; D012701:Serotonin; D011388:Prolactin; D013006:Growth Hormone